Combination Therapy of Paracetamol + Meloxicam for Chronic Musculoskeletal Pain

1. Initial Paracetamol Therapy

Start scheduled paracetamol 650–1000 mg every 6 h (max 3 g/day in adults ≥ 60 years, 4 g/day in younger adults) as first‑line analgesia for chronic musculoskeletal pain. This dosing provides steady plasma levels and superior pain control compared with PRN dosing. [@1]
Paracetamol yields an effect size of 0.21 for pain relief with a number‑needed‑to‑treat of 2 and demonstrates excellent cardiovascular, renal, and gastrointestinal safety. [@1]
If adequate analgesia is not achieved after 2–4 weeks of optimal paracetamol dosing, escalation to combination therapy should be considered. [@3]

Add meloxicam 7.5 mg once daily while continuing scheduled paracetamol when pain remains uncontrolled after optimized paracetamol dosing. This step introduces a COX‑2‑preferential NSAID to the regimen. [@1]
The combination produces additive analgesia (paracetamol effect size 0.21 + NSAID effect size 0.69), delivering superior pain relief versus either agent alone. [@1]
Prescribe the lowest effective NSAID dose for the shortest feasible duration and reassess pain and safety every 3 months. [@1]

Co‑prescribe a proton‑pump inhibitor (e.g., omeprazole 20 mg daily) with meloxicam; this reduces the relative risk of gastric ulcer from 5.36 to 0.40. Gastroprotection is required for all patients receiving NSAIDs, especially those ≥ 60 years. [@1]

Do not use meloxicam in patients with active peptic ulcer disease, severe renal impairment (eGFR < 30 mL/min), decompensated heart failure, or a recent myocardial infarction. [@5]
Meloxicam (and other NSAIDs) increase cardiovascular mortality in post‑MI patients, with hazard ratios ranging from 1.29 to 2.80, proportional to COX‑2 selectivity. [@5]
NSAIDs can cause fluid retention and precipitate acute decompensation in patients with heart failure. [@6]

Renal function (serum creatinine, eGFR) should be measured at baseline, 1–2 weeks after meloxicam initiation, and then every 3–6 months. [@4]
Blood pressure must be checked at each visit, as NSAIDs may raise BP and blunt the effect of antihypertensives (especially ACE inhibitors). [@4]
Assess for gastrointestinal symptoms (dyspepsia, abdominal pain, melena) at every encounter; discontinue meloxicam immediately if bleeding is suspected. [@1]
If paracetamol is used near maximal daily doses for several weeks, monitor liver enzymes to detect potential hepatotoxicity. [@3]

Never exceed 3 g/day total paracetamol in adults ≥ 60 years or 4 g/day in younger adults, counting all sources (including OTC cold remedies). [@3]
The FDA limits prescription combination products to 325 mg paracetamol per dosage unit to prevent inadvertent overdose. [@3]
Avoid diclofenac because it carries a higher risk of cardiovascular events compared with other traditional NSAIDs. [@5]
If the patient is on low‑dose aspirin, separate meloxicam administration by at least 2 hours to preserve aspirin’s antiplatelet effect. [@4]
Discontinue meloxicam promptly if acute kidney injury, new‑onset fluid retention, hypertension, or signs of heart‑failure develop. [@6]

The stepped‑care algorithm (paracetamol first, then NSAID addition) is endorsed by major societies including EULAR, ACC/AHA, and the American Geriatrics Society. This reflects high‑quality guideline consensus. [@5]
Paracetamol’s lower analgesic efficacy (effect size 0.21) versus NSAIDs (effect size 0.69) is offset by its superior safety profile, justifying its role as first‑line therapy. [@1]
Combining paracetamol with meloxicam enables reduction of the NSAID dose while maintaining adequate analgesia, thereby lowering dose‑dependent cardiovascular and renal toxicity. [@3]
Observational links between paracetamol and adverse cardiovascular/renal outcomes are likely confounded by indication bias; randomized trials show no increase in such toxicity at therapeutic doses. [@1]